Unique ID issued by UMIN | UMIN000051698 |
---|---|
Receipt number | R000054656 |
Scientific Title | Cardiovascular adverse events in lung cancer patients receiving immune checkpoint inhibitor therapy: An analysis of a nationwide electronic medical record data |
Date of disclosure of the study information | 2023/08/30 |
Last modified on | 2024/01/23 09:01:05 |
Cardiovascular adverse events in lung cancer patients receiving immune checkpoint inhibitor therapy: An analysis of a nationwide electronic medical record data
CARE in ICI therapy
Cardiovascular adverse events in lung cancer patients receiving immune checkpoint inhibitor therapy: An analysis of a nationwide electronic medical record data
CARE in ICI therapy
Japan |
Patients with primary lung cancer
Cardiology | Pneumology | Hematology and clinical oncology |
Malignancy
NO
The incidence, clinical characteristics, and risk factors of cardiovascular adverse events during immune checkpoint inhibitor (ICI) therapy in primary lung cancer patients have not been adequately evaluated since these adverse events are not common. This study aims to investigate the impact of ICI therapy on clinically evident cardiovascular adverse events in patients with primary lung cancer using a nationwide electronic medical record data.
Safety
Exploratory
Pragmatic
Phase IV
The following outcomes that occur within 180 days after the index date.
1. Any myocarditis
2. Severe myocarditis, including fulminant form of myocarditis
3. Acute myocardial infarction, unstable angina pectoris, and spastic angina pectoris
4. Symptomatic arrhythmias
5. Pericarditis
6. Sudden death and acute cardiac death
7. Acute heart failure requiring hospital admission
8. Deep vein thrombosis
9. Takotsubo cardiomyopathy
Index date is defined as the time of the first ICI treatment (study group) or the time of the first start of predefined chemotherapy other than ICI (control group).
The following outcomes that occur within 180 days after the index date.
1. Myasthenia gravis
2. Myositis
3. Polymyalgia rheumatica,
4. Hyperthyroidism/Hypothyroidism
Observational
Not applicable |
Not applicable |
Male and Female
Patients with primary lung cancer
1) Patients with previous diagnosis of the following diseases are excluded from the analysis:
Multiple myeloma
BCR-ABL-positive chronic myelogenous leukemia
Cervical cancer
Ovarian cancer
Hepatocellular carcinoma
Gastric cancer
Rectal cancer
Colon cancer
3)Patients without a 180-day look-back period commencing at the time of first ICI treatment (study group) or at the time of the first start of predefined chemotherapy other than ICI (control group).
2000
1st name | Tsuyoshi |
Middle name | |
Last name | Isawa |
Sendai Kousei Hospital
Cardiology Department
980-0871
Hirosemachi 4-15, Sendai city, Miyagi prefecture, Japan
+81222226181
isa_tsuyo@yahoo.co.jp
1st name | Tsuyoshi |
Middle name | |
Last name | Isawa |
Sendai Kousei Hospital
Cardiology Department
980-0871
Hirosemachi 4-15, Sendai city, Miyagi prefecture, Japan
+81222226181
isa_tsuyo@yahoo.co.jp
Sendai Kousei Hospital
None
Self funding
Sendai Kousei Hospital
Hirosemachi 4-15, Sendai city, Miyagi prefecture, Japan
+81222226181
isa_tsuyo@yahoo.co.jp
NO
2023 | Year | 08 | Month | 30 | Day |
Unpublished
No longer recruiting
2023 | Year | 07 | Month | 24 | Day |
2021 | Year | 08 | Month | 25 | Day |
2023 | Year | 07 | Month | 24 | Day |
2023 | Year | 11 | Month | 01 | Day |
This population-based, retrospective, observational cohort study utilized a real-word data database administered by the Health, Clinic, and Education Information Evaluation Institute (HCEI) (Kyoto, Japan) with the support of Real World Data, Co., Ltd. (Kyoto, Japan).
2023 | Year | 07 | Month | 24 | Day |
2024 | Year | 01 | Month | 23 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000054656